Molecule of the month: miRNA and Down's syndrome.

Paul Shapshak

doi:10.6026/97320630009752

Abstract

Molecule of the month: miRNA and Down's syndrome.

Highlights

The pathogenesis and molecular biology of Down’s syndrome miRNA densities per 10 megabases in humans vary are under intense study and advances have been made in the from 7.42 on chromosome 1, 29.26 on chromosome 19, and 5.40 care of patients with Down’s syndrome
The,phosphatidylinositol-binding clathrin assembly protein chromosome 21 fragment is from the 21q22 band-region and (PICALM), cyclin-dependent kinase inhibitor 2A (CDKN2A), causes a triplication of that 1,000 bp portion of chromosome 21. glutamate receptor, ionotropic, N-methyl d-aspartate subunit
They have been identified in phosphorylation regulated kinase 1A gene (Dyrk1a), and several cell processes including DNA damage, synapse nuclear factor of activated T-cells (NFAT)

Summary

Introduction

The pathogenesis and molecular biology of Down’s syndrome miRNA densities per 10 megabases in humans vary are under intense study and advances have been made in the from 7.42 on chromosome 1, 29.26 on chromosome 19, and 5.40 care of patients with Down’s syndrome. This leads expression of the above five miRNAs in Down’s syndrome to chromosome 21 trisomy. There is an inherited include the following proteins: methyl CpG binding protein 2 form of Down’s syndrome that is due to translocation of a (MeCP2), complement factor H (CFH), sirtuin 1 (SIRT1)

Results

Conclusion